2014
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy (Journal article)
Mora-Peris, B., Watson, V., Vera, J. H., Weston, R., Waldman, A. D., Kaye, S., . . . Winston, A. (2014). Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 69(6), 1642-1647. doi:10.1093/jac/dku018DOI: 10.1093/jac/dku018
The clinical pharmacology of Human Immunodeficiency Virus (HIV) therapy failure (Thesis / Dissertation)
Watson, V. (2014). The clinical pharmacology of Human Immunodeficiency Virus (HIV) therapy failure. (PhD Thesis, University of Liverpool).
2013
Santos, J. R., Muñoz-Moreno, J. A., Moltó, J., Prats, A., Curran, A., Domingo, P., . . . Clotet, B. (2013). Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.. PloS one, 8(7), e70201. doi:10.1371/journal.pone.0070201DOI: 10.1371/journal.pone.0070201
Rilpivirine concentrations in seminal plasma in HIV infected patients (Poster)
Watson, V., Mora-Peris, B., Tjia, J., Vera, J. H., Weston, R., Khoo, S., . . . Winston, A. (2013). Rilpivirine concentrations in seminal plasma in HIV infected patients. Poster session presented at the meeting of 14th International Workshop on Clinical Pharmacology of HIV Therapy. Netherlands.
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention (Journal article)
Jackson, A., Moyle, G., Watson, V., Tjia, J., Amara, A., Back, D., . . . Boffito, M. (2013). Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 62(3), 275-281. doi:10.1097/QAI.0b013e3182829bd0DOI: 10.1097/QAI.0b013e3182829bd0
2012
Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP) (Journal article)
Watson, V., Else, L., Tjia, J., Khoo, S., & Back, D. (2012). Development and validation of a LC‐MS/MS assay to quantify intracellular tenofovir‐diphosphate (TFV‐DP) and emtricitabine‐triphosphate (FTC‐TP). Journal of the International AIDS Society, 15(S4), 1. doi:10.7448/ias.15.6.18336DOI: 10.7448/ias.15.6.18336
Dickinson, L., Jackson, A., Garvey, L., Watson, V., Khoo, S., Boffito, M., . . . Back, D. (2012). Simultaneous population pharmacokinetic modelling of darunavir and ritonavir Once daily in HIV-infected patients: evaluation of lower ritonavir dose. Journal of the International AIDS Society, 15(4).
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval (Journal article)
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. Antimicrobial Agents and Chemotherapy, 56(9), 4583-4585.
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval. (Journal article)
Yilmaz, A., Watson, V., Dickinson, L., & Back, D. (2012). Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.. Antimicrobial agents and chemotherapy, 56(9), 4583-4585. doi:10.1128/aac.06311-11DOI: 10.1128/aac.06311-11
Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF) (Poster)
Watson, V., Tjia, J., Szwandt, S., Else, L., Khoo, S., & Back, D. (2012). Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). Poster session presented at the meeting of 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain.
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrobial Agents and Chemotherapy, 56(3), 1427-1433.
CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study. (Journal article)
Garvey, L., Nelson, M., Latch, N., Erlwein, O. W., Allsop, J. M., Mitchell, A., . . . Winston, A. (2012). CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.. The Journal of antimicrobial chemotherapy, 67(1), 206-212. doi:10.1093/jac/dkr427DOI: 10.1093/jac/dkr427
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study (Journal article)
Else, L., Jackson, A., Puls, R., Hill, A., Fahey, P., Lin, E., . . . Boffito, M. (2012). Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother, 56(3), 1427-1433.
2011
Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals (Journal article)
Jackson, A., Watson, V., Back, D., Khoo, S., Liptrott, N., Egan, D., . . . Boffito, M. (2011). Plasma and Intracellular Pharmacokinetics of Darunavir/Ritonavir Once Daily and Raltegravir Once and Twice Daily in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes, 58(5), 450-457. doi:10.1097/qai.0b013e3182364c67DOI: 10.1097/qai.0b013e3182364c67
Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology (Poster)
Watson, V., Liptrott, N., Egan, D., Dickinson, L., Tjia, J., Reynolds, H., . . . Back, D. (2011). Investigating variability in reported intracellular raltegravir concentrations: contribution of PBMC isolation methodology. Poster session presented at the meeting of 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, USA.
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. (Journal article)
Jackson, A., D'Avolio, A., Watson, V., Bonora, S., Back, D., Taylor, J., . . . Boffito, M. (2011). Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.. The Journal of antimicrobial chemotherapy, 66(4), 885-889. doi:10.1093/jac/dkq546DOI: 10.1093/jac/dkq546
Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients (Journal article)
Molto, J., Valle, M., Back, D., Cedeno, S., Watson, V., Liptrott, N., . . . Clotet, B. (2011). Plasma and Intracellular (Peripheral Blood Mononuclear Cells) Pharmacokinetics of Once-Daily Raltegravir (800 Milligrams) in HIV-Infected Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(1), 72-75. doi:10.1128/AAC.00789-10DOI: 10.1128/AAC.00789-10
2010
Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. (Journal article)
Yilmaz, A., Verhofstede, C., D'Avolio, A., Watson, V., Hagberg, L., Fuchs, D., . . . Gisslén, M. (2010). Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.. Journal of acquired immune deficiency syndromes (1999), 55(5), 590-596. doi:10.1097/qai.0b013e3181f5b3d1DOI: 10.1097/qai.0b013e3181f5b3d1
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds (Journal article)
Else, L., Watson, V., Tjia, J., Hughes, A., Siccardi, M., Khoo, S., & Back, D. (2010). Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 878(19), 1455-1465. doi:10.1016/j.jchromb.2010.03.036DOI: 10.1016/j.jchromb.2010.03.036
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans (Journal article)
Wakeham, K., Parkes-Ratanshi, R., Watson, V., Ggayi, A. -B., Khoo, S., & Lalloo, D. G. (2010). Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 65(2), 316-319. doi:10.1093/jac/dkp451DOI: 10.1093/jac/dkp451
2009
Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients. (Journal article)
Yilmaz, A., Watson, V., Else, L., & Gisslèn, M. (2009). Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.. AIDS (London, England), 23(18), 2537-2540. doi:10.1097/qad.0b013e328333ae0eDOI: 10.1097/qad.0b013e328333ae0e
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. (Journal article)
Boffito, M., Jackson, A., Lamorde, M., Back, D., Watson, V., Taylor, J., . . . Pozniak, A. (2009). Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.. Journal of acquired immune deficiency syndromes (1999), 52(2), 222-227. doi:10.1097/qai.0b013e3181b061d0DOI: 10.1097/qai.0b013e3181b061d0
Undated
Watson, V. (n.d.). The clinical pharmacology of Human Immunodeficiency Virus (HIV) therapy failure. (PhD Thesis, University of Liverpool).
